BiomniBench: Process-level Evaluation of LLM Agents for Real-world Biomedical Research

Qu, Y.; Lu, Y.; Tu, X.; Zhang, S.; She, T.; Shaw, A. G.; Shih, J.-H.; Zhao, B.; Shen, M.; Yang, H.; Yan, J.; Zhang, R.; Wu, X.; Li, T.; Cong, L.; Hu, X.; Jiang, Y.; Dong, J.; Peng, T.; Leskovec, J.; Huang, K.

doi:10.64898/2026.05.12.724604

Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.05.12.724604

BiomniBench: Process-level Evaluation of LLM Agents for Real-world Biomedical Research

View original source ↗Export metadata ↓

Abstract

LLM agents now perform real biomedical research, but evaluating them rigorously is hard. Outcome-only benchmarks fail in two ways. First, a correct final answer can come from memorization, reward hacking, or wrong reasoning that produces the right number by chance. Second, valid alternative analyses are marked wrong simply because they differ from the reference. We introduce BiomniBench, a process-level evaluation framework that scores the full agent trajectory against expert-designed, task-specific rubrics. Our first release, BiomniBench-DA, contains 100 data-analysis tasks across 17 task types, 5 disease areas, and a general-biology category, each based on a paper from journals such as Nature, Cell, and Science and co-developed with an original author or a domain expert. Benchmarking frontier and open-weight models across four agent harnesses reveals three findings. Frontier and open-weight bases cluster within a few points of each other, with substantial headroom for all models. The agent harness shifts scores by more than the gap between successive model generations. Agents reliably ground claims in real sources yet consistently fall short on method selection, biological interpretation, and scientific reasoning. BiomniBench is the first process-level benchmark for LLM agents in biomedical research, providing the dimension-level diagnostics that outcome scoring cannot. Datasethuggingface.co/datasets/phylobio/BiomniBench-DA

Explore related subjects

bioinformatics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Qu, Y., Lu, Y., Tu, X., Zhang, S., She, T., Shaw, A. G., Shih, J.-H., Zhao, B., Shen, M., Yang, H., Yan, J., Zhang, R., Wu, X., Li, T., Cong, L., Hu, X., Jiang, Y., Dong, J., Peng, T., Leskovec, J., Huang, K.. 2026-05-14. BiomniBench: Process-level Evaluation of LLM Agents for Real-world Biomedical Research. https://doi.org/10.64898/2026.05.12.724604

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Senescence-associated KRAS upregulation in peripheral T cells links to premature coronary artery disease

Aims: Premature coronary artery disease (PCAD) lacks specific molecular drivers, and the role of immunosenescence is unclear. We investigated whether aging-related gene dysregulation in T cells contributes to PCAD. Methods: We combined bulk transcriptomics of PBMCs from 12 PCAD patients and 21 controls, single-cell RNA sequencing of PBMCs and human atherosclerotic plaques, weighted gene co-expression network analysis, gene perturbation network analysis, and molecular docking. Results: KRAS was identified as a hub gene intersecting PCAD-associated genes and aging-related genes. Single-cell analysis showed KRAS upregulation predominantly in effector CD8+ T cells, which exhibited the highest senescence scores that were further elevated in disease. Network perturbation of KRAS strongly impacted the cell killing pathway. KRAS-high effector CD8+ T cells were detected in coronary and carotid plaques, displaying enhanced cytotoxicity, exhaustion, and senescence features. Additionally, a candidate small molecule was computationally predicted to bind inactive KRAS. Conclusions: Elevated KRAS expression in senescent, cytotoxic CD8+ T cells is associated with PCAD, bridging immunosenescence and premature atherosclerosis. This finding provides a novel biomarker candidate and potential therapeutic entry point, awaiting further functional validation.

bioinformatics↗

bioRxiv2026

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗

bioRxiv2026

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗